Abstract
Introduction: SABA over-use in asthma is harmful for patients and the environment. The SENTINEL Project utilised a co-designed intervention to identify and address SABA over-use with the aim of improving patient outcomes and reducing the environmental impact of asthma and its treatment. SENTINEL Plus is the scaled implementation of the same co-designed intervention across Primary Care organisations in England.
Aims and Objectives: To characterise the first 25 primary care sites to adopt SENTINEL Plus and assess changes in prescribing practice post-implementation.
Methods: Prescribing data (openprescribing.net) were analysed for the months July 2020 to October 2022 inclusive. Post-SENTINEL Plus implementation data were compared with the matched months pre-implementation.
Results: The first 25 SENTINEL Plus adopting practices had mean 11.2 months follow-up data post-implementation. 10,481 fewer SABA inhalers (p<0.05) and 5,978 more ICS containing inhalers (p≤0.001) were prescribed post implementation than would be expected if prescribing had remained unchanged from pre-SENTINEL Plus levels. Practice and prescribing data are presented in Table 1.
Conclusions: SENTINEL Plus implementation across geographically diverse primary care practices in England was associated with a significant reduction in SABA and increased ICS prescribing, concordant with improved asthma prescribing practice.
Footnotes
Cite this article as: European Respiratory Journal 2023; 62: Suppl. 67, PA5289.
This abstract was presented at the 2023 ERS International Congress, in session “Inflammatory endotyping: the macrophage across disease areas”.
This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).
- Copyright ©the authors 2023
